Tokai Pharmaceuticals is a biopharmaceutical company previously focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. Enrollment in the ARMOR2 and ARMOR3-SV clinical trials of Tokai’s drug candidate, galeterone, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) has been closed, with only patients in ARMOR2 long-term extension continuing treatment at this time.  Assessment of plans for galeterone, the ARDA platform and Tokai’s AR-V7 assay work are underway at this time.

On December 22, 2016, Tokai and Otic Pharma Ltd., a privately-held, clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose, and throat (ENT), announced that the two companies have entered into a definitive share purchase agreement under which the shareholders of Otic Pharma will become the majority owners of Tokai.